Nanobiotix Shares Soar 5% and Aim for Record Highs

A Technical Recovery Moving Away from Short-Term Moving Averages

Nanobiotix shares gained 4.99% to €34.92 during the session, marking a weekly gain of 8.22%. The stock has significantly risen above its MM20 (€30.72) and MM50 (€33.06), with a gap of 5.63% from the latter. This movement is an extension of the rebound that began earlier in the week, following the brief on June 30th which already pointed to a return to the MM50 of €32.70. The RSI at 58 supports the rise without indicating any particular tension, while the stock approaches the resistance identified at €36.64. Over twelve months, the performance remains exceptional, with a gain close to 697%. The stock is among the top performers of the SBF 120, while the broad index is up 0.58% and the CAC 40 increases by 0.49%. The Paris session benefits from a calm market environment, with a VIX at 15.78 and a significant easing of oil prices, with Brent returning to around $70 per barrel.

Annual Rally Backed by Clinical Advancements in JNJ-1900 and Strengthening of Cash Reserves

The underlying momentum of the stock is driven by the advancement of clinical studies on JNJ-1900 (NBTXR3), identified as a key opportunity during the Q1 2026 report (June 2, 2026). The company had also highlighted the strengthening of its Nanoprimer platform, while pointing out the limitations of the current standard of care in inoperable NSCLC among the risks. To recall, Nanobiotix had also communicated in early June on encouraging preliminary results in phase 2 and a strengthening of its cash reserves, elements that supported the stock in the period following the mid-May record. The dual listing on Paris/Nasdaq (via ADS NBTX) remains a factor in the stock's performance, with both lines moving strongly correlated. In the short term, the sustainable crossing of the resistance at €36.64 remains the next technical milestone, while the MM200 at €23.78 represents a long-term base now distanced by nearly 47% from the current price.